New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reaction The US FDA recently approved Xolair as the first and only medicine for children and adults with one or […]

Related Keywords

United States , American , Parag Mahanti , Michael Meo , Marlena Abdinoor , America Julie Masow , Jonathan Graham , R Sharon Chinthrajah , Angelika Jahreis , Sloan Simpson , Robert Wood , Genentech , National Institute Of Allergy , Genentech Inc , Drug Administration , Seann Parker Center , American Academy Of Allergy , Roche Group , Eudowood Division Of Allergy , Public Health Impact Of Parent , Consortium For Food Allergy Research Co , Facebook , Novartis , Instagram , Exchange Commission , National Institutes Of Health , Johns Hopkins Children Center , Stanford School Of Medicine , Novartis Pharmaceuticals Corporation , Asthma Research , Inspection Service , Linkedin , Development Unit Head , National Institutes , New England Journal , Eudowood Division , Johns Hopkins Children , Associate Professor , Stanford School , Secondary Endpoints Results , Pediatric Population , Key Secondary , Additional Secondary , Adjunct Therapy , Food Allergic Children , National Institute , Infectious Diseases , Food Allergy Research , Novartis Pharmaceuticals , Important Safety , Important Safety Information , Food Allergies Among , Public Health Impact , Parent Reported Childhood Food Allergies , Accessed November , Food Equivalents , Food Allergy , Environmental Factors , Accessed February ,